Trial Profile
A phase II study of Su011248 [sunitinib] in patients with recurrent and/or metastatic squamous head and neck carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 09 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Nov 2009 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
- 03 Nov 2009 Planned number of patients changed from 37 to 54 as reported by ClinicalTrials.gov.